One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Table of Contents
doi : 10.1016/S0923-7534(25)04911-7
Volume 36, Issue 11, November 2025, Pages i-ii
Toward risk-adjusted CT schedules in first-line metastatic colorectal cancer
Shaping the future of 177Lu-PSMA-617 radiopharmaceutical therapy in prostate cancer: is earlier better, or is patient selection key?
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
Clinical challenges and proposed solutions for patients with invasive lobular breast cancer
Cancer of unknown primary site and TNM staging: a new paradigm for patient management
Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments―analysis of 11 trials by AIO and GONO☆
Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer
Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer
Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials
Re-examining post-operative chemoradiotherapy in head and neck cancer: an updated long-term combined analysis of RTOG 9501/EORTC 22931
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis
Incidence trends and long-term survival in early-onset colorectal cancer: a nationwide Swedish study
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial☆
Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline
Navigating the limits of ribociclib in early breast cancer: questions from the NATALEE trial
Rethinking ribociclib: revisiting dosing, duration, and the N0 high-risk dilemma in the NATALEE trial
Reply to Letters to the Editor by Mimura et al. and Hu and Yang regarding the NATALEE final invasive disease-free survival analysis
The OpeRa trial: the active role of the patient in the clinical decision-making process and surgical planning
Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRASG12C inhibitors
Mechanisms of genomic resistance across emerging classes of KRAS inhibitors
